Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 211

Sort by

Sort Order Select

Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood blood.2024025987.

https://doi.org/10.1182/blood.2024025987

Published: 2024

Includes: Supplemental data

Journal Articles

Not so natural, not so killers

Bruno Paiva, José-Angel Martinez-Climent

Blood (2024) 144 (12): 1238–1240.

https://doi.org/10.1182/blood.2024025597

Published: 2024

Journal Articles

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma

Blood blood.2024024995.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

RASping myeloma genomics

Bruno Paiva, María-José Calasanz

Blood (2024) 144 (2): 129–131.

https://doi.org/10.1182/blood.2024024869

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Single Cell Analysis Identifies Expression of PD-L2 on Human Bone Marrow Hematopoietic Stem Cells

Tessa Schmachtel, Marius Külp, Weijia Yu, Hana Komic, Catia Simoes, Malin S. Nilsson, Felipe Prosper, Timm Schroeder, Halvard Bonig, Bruno Paiva, Fredrik B. Thorén, Michael A. Rieger

Blood (2023) 142 (Supplement 1): 2671.

https://doi.org/10.1182/blood-2023-188684

Published: 2023

Journal Articles

Comprehensive Characterization of the Bone Marrow Microenvironment Transcriptional Remodeling in the Progression from MGUS to Smoldering and Multiple Myeloma

Blood (2023) 142 (Supplement 1): 88.

https://doi.org/10.1182/blood-2023-178534

Published: 2023

Journal Articles

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Blood (2023) 142 (Supplement 1): 533.

https://doi.org/10.1182/blood-2023-185737

Published: 2023

Journal Articles

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Blood (2023) 142 (Supplement 1): 2958.

https://doi.org/10.1182/blood-2023-188865

Published: 2023

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Blood (2023) 142 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2023-182887

Published: 2023

Journal Articles

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

Blood (2023) 142 (Supplement 1): 209.

https://doi.org/10.1182/blood-2023-179866

Published: 2023

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Blood (2023) 142 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2023-185614

Published: 2023

Journal Articles

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Jon Celay, Miriam Recalde, María Victoria Revuelta, Marta Larrayoz, Sara Rodriguez, Maria J Garcia-Barchino, Jennifer R. Chapman-Fredricks, Teresa Lozano, Juan J Lasarte, Ming Q. Du, Izidore S. Lossos, Sergio Roa, Aldo Roccaro, Miguel Canales, Felipe Prosper, Bruno Paiva, Leandro Cerchietti, Jose A. Martinez-Climent

Blood (2023) 142 (Supplement 1): 431.

https://doi.org/10.1182/blood-2023-173394

Published: 2023

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Aintzane Zabaleta, Noemi Puig, Maria Teresa Cedena Romero, Jose J Perez, Cristina Moreno, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Veronica Gonzalez-Calle, Lucia Lopez Corral, Beatriz Rey-Búa, Borja Puertas Martínez, Fatima Miras, Jose Sanchez-Pina, Nieves Lopez, Joaquin Martinez-Lopez, Maria Victoria Mateos, Jesus San-Miguel, Bruno Paiva

Blood (2023) 142 (Supplement 1): 94.

https://doi.org/10.1182/blood-2023-185980

Published: 2023

Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

Aintzane Zabaleta, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Marta Lasa, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Jesús San Miguel, Bruno Paiva, Esperanza Martín-Sánchez

Blood (2023) 142 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2023-182150

Published: 2023

Journal Articles

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 339.

https://doi.org/10.1182/blood-2023-186916

Published: 2023

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

NARROW

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Not so natural, not so killers

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma

RASping myeloma genomics

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Single Cell Analysis Identifies Expression of PD-L2 on Human Bone Marrow Hematopoietic Stem Cells

Comprehensive Characterization of the Bone Marrow Microenvironment Transcriptional Remodeling in the Progression from MGUS to Smoldering and Multiple Myeloma

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only